Risk Management and the Impact of EN ISO 14971:2012 Annex Z

Similar documents
ISO 14971: Overview of the standard

Medical Device Software Do You Understand How Software is Regulated?

Risk Assessment for Medical Devices. Linda Braddon, Ph.D. Bring your medical device to market faster 1

BSI Road Show: September 8 th to 15 th, 2014

Medical Devices. Notified Bodies and the CE certification Process for Medical Devices. European Surgical Robotics Demonstration Day

Reporting Changes to your Notified Body

Vigilance Reporting. Vicky Medley - Head of QMS, Medical Devices. September Copyright 2015 BSI. All rights reserved.

Clinical evaluation Latest development in expectations EU and USA

GUIDELINES ON MEDICAL DEVICES EVALUATION OF CLINICAL DATA : A GUIDE FOR MANUFACTURERS AND NOTIFIED BODIES

Want to know more about the Notified Body?

GUIDANCE NOTE FOR MANUFACTURERS OF CUSTOM-MADE MEDICAL DEVICES


Medical Device Software Standards for Safety and Regulatory Compliance

Information supplied by the manufacturer with medical devices

Risk Management in IEC rd Edition. Presented by Alberto Paduanelli Medical Devices Lead Auditor, MHS-UK, TÜV SÜD Product Service

Risk Assessment Tools for Identifying Hazards and Evaluating Risks Associated with IVD Assays

GUIDELINES ON MEDICAL DEVICES

UNDERSTANDING THE EC DIRECTIVE 98/79/EC ON IN VITRO DIAGNOSTIC MEDICAL DEVICES

Title: Basic Principles of Risk Management for Medical Device Design

Space project management

How To Know If A Mobile App Is A Medical Device

Guidance for manufacturers and Notified Bodies on reporting of Design Changes and Changes of the Quality System

Quality Risk Management - The Medical Device Experience. Niamh Nolan Principal Design Assurance Engineer Boston Scientific

Medical Software Development. International standards requirements and practice

FINAL DOCUMENT. Implementation of risk management principles and activities within a Quality Management System. The Global Harmonization Task Force

9100:2016 Series of Standards Frequently Asked Questions (FAQs)

Medical Device Directive 2007/47/EC What is New? Are we moving towards Drug Rules?

WHITEPAPER: SOFTWARE APPS AS MEDICAL DEVICES THE REGULATORY LANDSCAPE

Manual for ITC's clients, Conformity assessment of ACTIVE IMPLANTABLE MEDICAL DEVICES pursuant to Council Directive 90/385/EEC

RECALLS in EUROPE. Past, present, near & further future. Gert Bos BSI Medcon May 2012

PROPOSED DOCUMENT. Quality management system Medical devices Nonconformity Grading System for Regulatory Purposes and Information Ex-change

Safety Risk Management in RT: A Software Manufacturer Perspective

Med-Info. Council Directive 93/42/EEC on Medical Devices. TÜV SÜD Product Service GmbH

CE Marking and Technical Standardisation

FMEA and FTA Analysis

ISO 9001:2000 Gap Analysis Checklist

Medical Devices: CE Marking Step-by Step

CAPA - the importance of data analysis

QUALITY RISK MANAGEMENT (QRM): A REVIEW

ISO 13485:201x What is in the new standard?

ISO 14971:2012 Ensuring Compliance to Annex Z Requirements

Controlling Risks Risk Assessment

Introduction into IEC Software life cycle for medical devices

Supplier Quality Management System Audit Checklist (ISO 9000:2000, TS 16949:2002)

Quality Risk Management ICH Q9 & ISO Presented by Michael Kerr 11 th November 2011

Quality Management System Certification. Understanding Quality Management System (QMS) certification

Design Verification The Case for Verification, Not Validation

Guidance for Industry: Quality Risk Management

PABIAC Safety-related Control Systems Workshop

Failure Analysis Methods What, Why and How. MEEG 466 Special Topics in Design Jim Glancey Spring, 2006

Bringing Legacy Medical Devices into Usability Compliance. Shannon Clark 4/29/2015

Deviation Handling and Quality Risk Management

BSI Unannounced Audits

Safety Regulation Group SAFETY MANAGEMENT SYSTEMS GUIDANCE TO ORGANISATIONS. April

Preparing yourself for ISO/IEC

ALL Medical Devices regardless of Classification

GUIDANCE NOTES FOR MANUFACTURERS OF CLASS I MEDICAL DEVICES

The New Paradigm for Medical Device Safety. Addressing the Requirements of IEC Edition 3.1

GENERIC STANDARDS CUSTOMER RELATIONSHIPS FURTHER EXCELLENCE CUSTOMISED SOLUTIONS INDUSTRY STANDARDS TRAINING SERVICES THE ROUTE TO

ISO & ISO Legal Compliance Know Your Risk - Reduce your Risk"

ISO 9001:2008 Quality Management System Requirements (Third Revision)

ISO Revisions Whitepaper

INTRODUCTION TO ISO 9001 REVISION - COMMITTEE DRAFT

ISO 9001:2008 Internal Audit & Gap Analysis Checklist

How To Write Software

GUIDELINES ON A MEDICAL DEVICES VIGILANCE SYSTEM

GUIDELINES ON A MEDICAL DEVICES VIGILANCE SYSTEM

Improved Utilization of Self-Inspection Programs within the GMP Environment A Quality Risk Management Approach

Software-based medical devices from defibrillators

Process Mapping and Process- Based Internal Audits

Quality Risk Management

ISO-9001:2000 Quality Management Systems

ISO 9001:2000 AUDIT CHECKLIST

Document: ISO/TC 176/SC 2/N 1147

IVD Regulation Overview. Requirements to Assure Quality & Effectiveness

V1.0 - Eurojuris ISO 9001:2008 Certified

ISO 9001:2008 Audit Checklist

ISO 9001 : 2008 QUALITY MANAGEMENT SYSTEM AUDIT CHECK LIST INTRODUCTION

How to Use the Design Process to Manage Risk: Elements of Design Controls and Why It Matters

ICH guideline Q10 on pharmaceutical quality system

Quality Risk Management in Pharmaceutical Industry: A Review

Medical Device Reporting (MDR) Requirements the New FDA Draft Guidance

ICH Q9 Quality Risk Management - an industry view. Peter H. Gough, Eli Lilly and Company

ISO 9001:2015 QUALITY MANAGEMENT SYSTEM ***** ISO 14001:2015 ENVIRONMENTAL MANAGEMENT SYSTEM

Designing an Effective Risk Matrix

Preparation for ISO OH&S Management Systems

Safety Management Systems (SMS) guidance for organisations

DNV GL Assessment Checklist ISO 9001:2015

Media fills Periodic performance qualification (Re-Validation)

TG TRANSITIONAL GUIDELINES FOR ISO/IEC :2015, ISO 9001:2015 and ISO 14001:2015 CERTIFICATION BODIES

4. Critical success factors/objectives of the activity/proposal/project being risk assessed

Operating instructions Diffuse reflection sensor with background suppression O1D101 O1D / / 2012

Safety and functional safety A general guide

Preparing for Unannounced Inspections from Notified Bodies

Quality Management System Certification. Understanding Quality Management System (QMS) certification

Quality Risk Management The Pharmaceutical Experience Ann O Mahony Quality Assurance Specialist Pfizer Biotech Grange Castle

BEST PRACTICE FOR THE DESIGN AND OPERATION OF HIGH HAZARD SITES

Risk Analysis Fanless Slim Medical Panel PC, models xxxx-onyx-2121dtyxxxxxxx

Transcription:

Risk Management and the Impact of EN ISO 14971:2012 Annex Z BSI 2014 Medical Device Mini-Roadshow Ibim Tariah Ph.D Technical Director, Healthcare Solutions Copyright 2014 BSI. All rights reserved. 1

Risk Management - Impact of Annex Z Overview of ISO 14971:2007 EN ISO 14971:2012 Harmonized Standard Differences from ISO Standard and 2009 version Deviations Presumption of Conformity BSI Audits FAQs Regarding EN ISO 14971:2012* * Included in presentation materials but not discussed Copyright 2014 BSI. All rights reserved. 2

ISO 14971:2007 Medical Devices Application of Risk Management to Medical Devices Copyright 2014 BSI. All rights reserved. 3

Definitions Risk = Combination of the probability of occurrence of harm and the severity of that harm Harm = Physical injury or damage to the health of people, or damage to property, or the environment Severity Low High No harm Death / Serious Injury Occurrence Improbable Frequent < X% Y Z% (Sometimes factor of occurrence of hazard x % of harm / hazard) Copyright 2014 BSI. All rights reserved. 4

ISO 14971 Main body (Clauses 1-3) 1 Scope 2 Terms and definitions 3 General requirements for risk management 3.1 Risk management process 3.2 Management responsibilities 3.3 Qualification of personnel 3.4 Risk management plan 3.5 Risk management file Copyright 2014 BSI. All rights reserved. 5

ISO 14971 Main body (Clauses 4-9) Clause 4: Risk analysis Clause 9: Post-production information Clause 5: Risk evaluation Clause 8: Risk management report Clause 6: Risk control Clause 7: Residual risk evaluation Copyright 2014 BSI. All rights reserved. 6

ISO 14971 Overview of Annexes Annex A Annex B Annex C Annex D Annex E (informative) Rationale for requirements (informative) Overview of the risk management process for medical devices (informative) Questions that can be used to identify medical device characteristics that could impact on safety (informative) Risk concepts applied to medical devices (informative) Examples of hazards, foreseeable sequences of events and hazardous situations risk control benefit estimation qualitative analysis ALARP probability Copyright 2014 BSI. All rights reserved. 7

ISO 14971 Overview of Annexes Annex F Annex G Annex H Annex I Annex J (informative) Risk management plan (informative) Information on risk management techniques (informative) Guidance on risk management for in vitro diagnostic (IVD) medical devices (informative) Guidance on risk analysis process for biological hazards (informative) Information for safety and information about residual risk PHA FTA HACCP FMEA HAZOP Copyright 2014 BSI. All rights reserved. 8

Risk Management EU Requirements MDD AIMDD IVDD Copyright 2014 BSI. All rights reserved. 9

Medical Devices EU Risk Requirements Risks > Benefits Benefits > Risks Risks R B R B Benefits Copyright 2014 BSI. All rights reserved. 10

The Directives Where is Risk? Risk MDD 93/42/EEC ERs: 1 2 6 7.2, 7.4, 7.5, 7.6 8.1, 8.6 9.2, 9.3 11.2, 11.4 12.1, 12.5, 12.6, 12.7 13.5, 13.6 AIMDD 90/385/EEC ERs: 1 5 8 9 10 11 15 IVDD 98/79/EC ERs: A 1 2 B 1.2 2.1, 2.2, 2.5, 2.7 3.2, 3.3, 3.4 5.3 6.2, 6.3, 6.4 7.1 8.6, 8.7 Total 41 18 24 Copyright 2014 BSI. All rights reserved. 11

EN ISO 14971:2012 EU harmonized standard for Risk Management Allows the presumption of conformity to MDD, AIMD, and IVD Published July 2012 & harmonized as of 30 August 2012. http://ec.europa.eu/enterprise/policies/european-standards/harmonised-standards/medicaldevices/index_en.htm Copyright 2014 BSI. All rights reserved. 12

What is the difference? ISO 14971:2007 The current International Standard EN ISO 14971:2009 The previous version of the European Harmonized Standard Obsolete as of 30 August 2012 EN ISO 14971:2012 The current European Harmonized Standard Changes within Foreword & Annex Zs only No change to requirements (Normative Text) i.e. clauses or requirements of the standard are exactly the same Copyright 2014 BSI. All rights reserved. 13

Why was EN ISO 14971:2012 created? A solution to formal objections raised by Swedish Competent Authority & European Commission on the harmonized status of a number of European Standards Revision of Annex Z s was made to provide greater clarity on applicability & alignment of ISO 14971 clauses with requirements of AIMDD, MDD & IVDD Copyright 2014 BSI. All rights reserved. 14

EN ISO 14971:2012 Z Annexes Example Annex ZA (MDD) Explains to which requirements, under which conditions and to what extent presumption of conformity can be claimed. Copyright 2014 BSI. All rights reserved. 15

EN ISO 14971:2009 Z Annexes (Now Obsolete) Compliance with all the requirement clauses in this standard will ensure that general aspects of medical devices related to patient risk and safety have been addressed. For particular medical devices or for particular safety aspects, additional specific requirements may need to be complied with in order to meet the essential requirements. Copyright 2014 BSI. All rights reserved. 16

EN ISO 14971:2012 Content Deviations Copyright 2014 BSI. All rights reserved. 17

EN ISO 14971:2012 Content Deviations Essential Requirements (ERs) Impacted Deviation MDD AIMDD IVDD 1 Treatment of negligible risks 1, 2, 6, 7.1 1, 5, 9 A.1, A.2, B.1.1 2 Discretionary power of mfr as to acceptability of risks 3 Risk reduction as far as possible vs. as low as reasonably practicable 4 Discretion as to whether a riskbenefit analysis needs to take place 5 Discretion as to the risk control options / measures 6 Deviation as to the first risk control option 7 Information of the users influencing the residual risk 1, 2, 6, 7.1 1, 5, 9 A.1, A.2, B.1.1 1, 2, 6, 7.1 1, 5, 6, 9 A.1, A.2, B.1.1 1, 6, 7.1 5 & 9 A.1 & B.1.1 2 & 7.1 - A.2 & B.1.1 2 & 7.1 - A.2 & B.1.1 2 & 7.1 - A.2 & B.1.1 Copyright 2014 BSI. All rights reserved. 18

Deviation No. 1 MDD (AIMDD) IVDD...all risks, regardless of their dimension, need to be reduced as much as possible (and need to be balanced, together with all other risks, against the benefit of the device). ISO 14971 D.8.2...the manufacturer may discard negligible risks. Copyright 2014 BSI. All rights reserved. 19

Were all risks considered for mitigation? Failure Mode Cause of Failure Local Effect System Effect Initial Rating Risk Control Measure(s) Risk Level RPN PRO SEV Hip Stem Surgeon implants a stem that is wrongly sized No tool available to determine needed size Unstable Implant Revision 8 1 8 X-ray templates provided for each implant size; implants marked with It is not sufficient just to determine that the risks are acceptable. It is also necessary to determine whether they have been reduced as far as possible. This can be stated line-by-line or categorically as a whole. size; clinical history of safety / performance Acceptable Broadly & Acceptable reduced as far as possible Copyright 2014 BSI. All rights reserved. 20

Deviation No. 2 MDD (AIMDD) IVDD...all risks have to be reduced as far as possible (and that all risks combined, regardless of any "acceptability" assessment, need to be balanced, together with all other risks, against the benefit of the device). ISO 14971 5, 6.4, 6.5 & 7...manufacturers have the freedom to decide upon the threshold for risk acceptability. D.6.1 only nonacceptable risks have to be integrated into the overall riskbenefit analysis. Copyright 2014 BSI. All rights reserved. 21

Are all risks reduced as far as possible? Unacceptable Extent of damage Management Review Required - ALARP 10 9 Broadly Acceptable 8 7 Some risks cannot be categorically ignored if risk can be reduced further. All risks must be reduced as far as possible. 6 5 4 3 2 1 1 2 3 4 5 6 7 8 9 10 Probability of occurrence Copyright 2014 BSI. All rights reserved. 22

Deviation No. 3 MDD AIMD IVD...risks to be reduced "as far as possible" without there being room for economic considerations. ISO 14971 3.4 & D.8 contains the concept of reducing risks "as low as reasonably practicable. The ALARP concept contains an element of economic consideration. Copyright 2014 BSI. All rights reserved. 23

Are all risks reduced as far as possible? Extent of damage 10 9 8 7 There must be another step ALARP concept should not allow economic factors to hinder mitigation, risks must be reduced as far as possible within stateof-the-art 6 5 4 3 2 1 1 2 3 4 5 6 7 8 9 10 Probability of occurrence Copyright 2014 BSI. All rights reserved. 24

Were risks reduced as far as possible? Failure Mode Cause of Failure Local Effect System Effect Initial Rating Risk Control Measure(s) Risk Level RPN PRO SEV Hip Stem Surgeon implants a stem that is wrongly sized No tool available to determine needed size Unstable Implant Revision 8 5 40 X-ray templates provided for every-other implant size; implants marked with size It is not reasonable in this example not to provide templates for each size. The economic impact of this should not be considered if this can reduce the risk. To make this determination, the state-of-the-art and available technology should be considered. ALARP Copyright 2014 BSI. All rights reserved. 25

Deviation No. 4 MDD AIMDD (IVDD)...an overall risk-benefit analysis must take place in any case, regardless of the criteria established in the mgmt plan of the mfr... (and requires undesirable side effects to "constitute an acceptable risk when weighed against the performance intended ). ISO 14971 6.5...an overall riskbenefit analysis does not need to take place if the overall residual risk is judged acceptable when using the criteria established in the risk mgmt plan. D.6.1 "A risk/benefit analysis is not required by this Int l Std for every risk. Copyright 2014 BSI. All rights reserved. 26

The Directives Where is Benefit? Benefit MDD 93/42/EEC ERs: 1 7.4 11.2 AIMDD 90/385/EEC ERs: 10 IVDD 98/79/EC ERs: A 1 Total 3 1 1 Risk 41 18 24 MEDDEV 2.7.1 Guidelines on Clinical Evaluation Report also discusses Risk / Benefit Analysis Copyright 2014 BSI. All rights reserved. 27

Risk / benefit analysis done for all risks? Frequent 2 Conduct Risk v Benefit Probable 6 4 Consider Risk v Benefit Occasional 3 Acceptable Remote 3 Improbable 2 There must be a risk benefit analysis for all risks and an overall risk benefit analysis not just unacceptable risks Copyright 2014 BSI. All rights reserved. 28

Documentation of Risk / Benefit Analysis Risk Management File o Combination of risk assessment / risk management report Clinical Evaluation Report (Frequently addressed here) Copyright 2014 BSI. All rights reserved. 29

Deviation No. 5 MDD IVDD... to select the most appropriate solutions...by applying cumulatively what has been called "control options or "control mechanisms" in the standard. ISO 14971 6.2...obliges the mfr to "use one or more of the following risk control options in the priority order listed. 6.4 indicates that further risk control measures do not need to be taken if, after applying one of the options, the risk is judged acceptable according to the criteria of the risk mgmt plan. Copyright 2014 BSI. All rights reserved. 30

All appropriate controls utilized? Failure Mode Cause of Failure Local Effect System Effect Initial Rating Risk Control Measure(s) Risk Level RPN PRO SEV Intracranial Pressure Monitor High pressure undetected Monitor does not indicate high pressure situation Brain damage No control measures mentioned about alarms / warnings for high pressure situation. The current mitigation is not considered to be sufficient as preventive measures could mitigate the risk. Death 10 4 40 Monitor provides continuous digital display of ICP; operates on AC & for up to 3 hrs on battery ALARP Copyright 2014 BSI. All rights reserved. 31

Deviation No. 6 MDD (IVDD)..."eliminate or reduce risks as far as possible (inherently safe design and construction)". ISO 14971 6.2... obliges the manufacturer to "use one or more of the following risk control options in the priority order listed: (a) inherent safety by design... without determining what is meant by this term. Copyright 2014 BSI. All rights reserved. 32

Were risks designed out if possible? Failure Mode Cause of Failure Local Effect System Effect SEV Initial Rating PRO RPN Risk Control Measure(s) Risk Level Mesh Mesh frays and suture pulls out Design of mesh / cutting edge Failed repair Risks must be designed out if possible. All risk control options must be applied until risks have been reduced as much as possible and any additional control option(s) do not improve the safety Revision 7 5 35 Warp IFU knit Acceptable mesh instructs & reduced design not to cut as far as prevents mesh and possible fraying not to after place cut; multiple sutures sizes closer available; than 5 suture mm to pullout edge testing Copyright 2014 BSI. All rights reserved. 33

Deviation No. 7 MDD (IVDD)...users shall be informed about the residual risks. This indicates that...the information given to the users does not reduce the (residual) risk any further. ISO 14971 2.15 & 6.4 residual risk is defined as the risk remaining after application of risk control measures. 6.2 regards "information for safety" to be a control option. Copyright 2014 BSI. All rights reserved. 34

Residual risks incorrectly reduced? Device Failure Mode Effect Initial Rating Risk Control Updated Rating RPN PRO SEV RPN PRO SEV Implant Emboli Death 4 3 12 IFU warning 4 1 4 A warning does not reduce the probability of occurrence of an emboli. Copyright 2014 BSI. All rights reserved. 35

Residual risks incorrectly reduced? Device Failure Mode Effect Initial Rating Risk Control Updated Rating RPN PRO SEV RPN PRO SEV Mesh with Barrier Membrane Device implanted upsidedown Adhesions 4 3 Instructions on how to use the device properly may mitigate the risk 12 IFU contains pictures / instructions on how to correctly orient device with marked side down 4 1 4 Copyright 2014 BSI. All rights reserved. 36

BSI Audits Copyright 2014 BSI. All rights reserved. 37

Conformity Assessment Quality System n=70 Americas n=50 EMEA n=40 Asia- Pacific External Resource n=as needed Microbiologist n=20 Technical Specialist n=80 Copyright 2014 BSI. All rights reserved. 38

BSI Audit Key Questions Are you aware of EN ISO 14971:2012? How are you ensuring you meet the directive requirements? Have you reviewed your existing Risk Management files, if needed? Is there a plan in place to do so? Copyright 2014 BSI. All rights reserved. 39

BSI Audit Key Questions Have all risks been reduced as far as possible? Has a risk benefit analysis been conducted for all risks? Have all risks been designed out if possible? Have risks been incorrectly reduced by warnings placed on IFUs or provided in training? Copyright 2014 BSI. All rights reserved. 40

Questions Copyright 2014 BSI. All rights reserved. 41

FAQs Regarding EN ISO 14971:2012 1. If our procedures were written to comply with ISO 14971:2007, do we have to change them? The normative part of the standard is identical. Most likely. The Z Annexes (ZA, ZB, and ZC) discuss deviations from the standard relative to the ability to comply with the MDD, AIMD, and IVDD. Therefore, additional steps must usually be taken in order to demonstrate compliance with the Essential Requirements (ERs) within the directives. In many cases, changes will need to be made to address the following (at a minimum): ensuring that ALL risks are reduced as far as possible; a risk/benefit analysis was conducted and considers all individual and overall risks; ALL risks have appropriate controls and the risks have been designed out if possible (MDD & IVDD only); risks have not been inappropriately reduced by labeling alone (MDD & IVDD only). Copyright 2014 BSI. All rights reserved. 43

FAQs Regarding EN ISO 14971:2012 2. Isn t the point of risk management to focus on the big risks? It is true that risk management activities have historically focused on identifying and reducing risks that have been unacceptable or were significant. However, the directives do not make distinctions in risk levels and simply refer to reducing ALL risks. Therefore, based on current thinking, in order to comply with the directives, the focus should be on reducing ALL risks. 3. As a manufacturer, how can we not take into account any economic considerations? It is understood that all risks cannot be eliminated and that the manufacturer is bound by the level of current technology and the state-of-the-art. It is also understood that a single device may not be intended for all individuals / applications and could be limited to certain populations. Therefore, the expectation is that if there are means to reduce risks for the intended use by available technologies and the state-of-the-art, that these measures should be taken. As risk management is also an active process that should continue to be evaluated post-production, if new technologies or the state-of-the-art change after the device was released, the question as to whether ALL risks have been reduced as far as possible should continue to be evaluated. Copyright 2014 BSI. All rights reserved. 44

FAQs Regarding EN ISO 14971:2012 4. Our QMS auditor said our RM procedures were effective and met EN ISO 14971:2012. We don t understand why the Technical Reviewer gave us a non-conformity for risk management. The primary responsibility for the QMS auditor is to review the manufacturer s procedures to ensure that they meet ISO 13485 and to sample records to ensure that the procedures have been executed appropriately. On the other hand, the primary responsibility for the Technical Reviewer is to review the output of the QMS system (i.e. Technical Documentation) and ensure that the product conforms to the applicable directive. Therefore, it is possible for the procedures and some of the records to have been updated to ensure compliance with EN ISO 14971:2012 but that the file(s) being reviewed by the Technical Reviewer do not demonstrate compliance with the directive. Copyright 2014 BSI. All rights reserved. 45

FAQs Regarding EN ISO 14971:2012 5. Do we have to change all our historical RM files or can we just address new product development and product changes? All files should be reviewed (based on a risk commensurate plan) to ensure that they comply with the directives and updated accordingly. Demonstration of compliance is expected. 6. Does BSI expect a line-by-line risk/benefit analysis? No. The manufacturer is expected to consider all individual risks and the overall risk in a risk / benefit analysis. How that is done is up to the manufacturer. BSI expects that the manufacturer documents (procedurally) how they intend to do this and executes this procedure. Copyright 2014 BSI. All rights reserved. 46

FAQs Regarding EN ISO 14971:2012 7. We have used a no-train, no-sale policy to reduce the risk of issues. Could this be used to reduce the probability of occurrence? Potentially. Deviation 7 only addresses not using information given to the users (i.e. in the IFU or through training) to reduce risks further. Therefore, if the training program is being used to teach the user proper operation of the device, this would most likely not be considered providing information to address residual risk. However, if this is being used as a forum to convey residual risk about the device, this would not be considered an appropriate way to mitigate risk. Copyright 2014 BSI. All rights reserved. 47

FAQs Regarding EN ISO 14971:2012 8. BSI agreed at the last design exam certification review that the RM files were acceptable and met the ERs. The device has not changed. Why is this not still acceptable? Harmonized standards are used as a method to convey state-of-the-art thinking on how compliance with the clauses of the standard confer a presumption of conformity with the associated directive and EFTA regulations. The Z Annexes explain to which requirements, under which conditions, and to what extent presumption of conformity can be claimed. Publishing of EN ISO 14971:2012 changed the state-of-the art view of these conditions. Therefore, while previous submissions may have allowed full presumption of conformity with the directives, this is no longer possible unless additional information is provided to address the deviations. Copyright 2014 BSI. All rights reserved. 48